Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
By implementing an axial hydro cyclone desilting can be done within the pressure pipe of hydropower plants.
The device produces a heavy swirling flow, the particles are carried radially outwards due to the centrifugal force and extracted after a short pathway.
The development of receptor tyrosine-kinase inhibitors (TKIs) in recent decades was a major step forward in cancer treatment. However, despite their clinical efficacy, therapy with TKIs is limited by strong side effects (such as skin rash) and development of resistance. New approaches are required
to overcome these drawbacks. Complexing the TK Inhibitor with Cobalt (Co3+) inactivates the inhibitor until it is released under the hypoxic conditions in the target tumour tissue. This approach promises effective treatment with considerably limited side effects. These complexes can be used as an alternative to existing
Epidermal Growth Factor Receptor (EGFR) Inhibitors, and were effective in tumour cells that have become resistant to conventional Treatments due to EGFR mutations like T790M.
The bone drilling apparatus effectively prevents overheating of the bone tissue by individually adjusting the coolant supply to the heat developed during a procedure. It implements a real-time measurement device, drill and regulating device for the coolant
pumping system.
This new 2D-actuator enables ultrasonic assisted drilling, milling or grinding of brittle-hard materials like ceramic, glass, silicium carbides or hardened
steel. It can be used in combination with existing machining centres. Operating at low frequency it allows the compensation of thermal and geometric faults at the workpiece as well.
According to new studies of a comet tail observed by NASA's Solar and Terrestrial Relations Observatory, or STEREO, the vacuum of interplanetary space is…
The human integrin avß6, which is usually undetectable in normal adults’ cells, but highly upregulated in different types of cancer, is an emerging target for therapy as well as imaging across several common tumor types. However, only few ligands are known so far that are highly active for avß6 integrin and at the same time possess no binding affinity toward other RGD-recognizing integrins. Furthermore, their metabolic instability, their high molecular weight and the complexity of their structures limit their medical application.
This problem could now be solved by the present invention. The peptides according to the invention show a remarkable affinity for avß6 and high selectivity against other integrins.